Kenneth A. Berlin J.D. Net Worth

Mr. Kenneth A. Berlin J.D. biography

Kenneth A. Berlin J.D. is the Pres, Interim CFO, CEO & Director at Ayala Pharmaceuticals.

What is the salary of Mr D?

As the Pres, Interim CFO y CEO & Director of Ayala Pharmaceuticals, the total compensation of Mr D at Ayala Pharmaceuticals is $1,162,449. There are no executives at Ayala Pharmaceuticals getting paid more.

How old is Mr D?

Mr D is 57, he's been the Pres, Interim CFO y CEO & Director of Ayala Pharmaceuticals since . There are 5 older and 4 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals Inc. is Richard Berman, 77, who is the Independent Director.

What's Mr D's mailing address?

Kenneth's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON,, NJ, 08540.

Insiders trading at Ayala Pharmaceuticals

Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... y Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.

What does Ayala Pharmaceuticals do?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kenneth A. Berlin J.D.,
  Pres, Interim CFO, CEO & Director
• Kenneth Berlin,
  President, Chief Executive Officer, Interim Chief Financial Officer, Director
• Andres Gutierrez,
  Chief Medical Officer and Executive Vice President
• Dr. Andres A. Gutierrez M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Roni Appel,
  Independent Director
• David Sidransky,
  Independent Chairman of the Board
• James Patton,
  Independent Non-Executive Vice Chairman of the Board
• Tim McCarthy,
  Investor Relations
• Samir Khleif,
  Independent Director
• Richard Berman,
  Independent Director
• Igor Gitelman CPA, CPA, M.B.A., MBA,
  Chief Accounting Officer & VP of Fin.
• Gregory T. Mayes,,
  Chief Operating Officer
• Robert J. Spiegel,
  Director
• Robert Petit,
  Chief Scientific Officer
• Sara Bonstein,
  Chief Financial Officer
• Thomas J Mckearn,
  Director
• Thomas J Ridge,
  Director
• Murray A Goldberg,
  Director
• Biotech Fund I, L.P.Israel ...,
  
• Capital Partners Gp, L.L.C....,
  
• Anthony A Lombardo,
  Interim CEO
• Molly Henderson,
  Executive Vice President & CFO
• Fredrick D Cobb,
  Vice President Finance
• John F Rothman,
  VP of Clinical Development
• David J Mauro,
  Chief Medical Officer
• Daniel J. O'connor,
  SVP, Legal & Business Dev Off
• Thomas A Moore,
  Director
• Christy Lee French,
  Exec. Dir. of Medical Affairs
• Mark J Rosenblum,
  Chief Financial Officer
• Biotech Fund I, L.P.Israel ...,
  
• Growth Fund Limited Partner...,
  10% owner
• Vered Bisker Leib,
  Director